Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis

Hoda Anton-Culver & Francesmary Modugno et al.

Abstract

Background

The role of ovulation in epithelial ovarian cancer (EOC) is supported by the consistent protective effects of parity and oral contraceptive use. Whether these factors protect through anovulation alone remains unclear. We explored the association between lifetime ovulatory years (LOY) and EOC.

Methods

LOY was calculated using 12 algorithms. Odds ratios (ORs) and 95% confidence intervals (CIs) estimated the association between LOY or LOY components and EOC among 26 204 control participants and 21 267 case patients from 25 studies. To assess whether LOY components act through ovulation suppression alone, we compared beta coefficients obtained from regression models with expected estimates assuming 1 year of ovulation suppression has the same effect regardless of source.

Results

LOY was associated with increased EOC risk (OR per year increase = 1.014, 95% CI = 1.009 to 1.020 to OR per year increase = 1.044, 95% CI = 1.041 to 1.048). Individual LOY components, except age at menarche, also associated with EOC. The estimated model coefficient for oral contraceptive use and pregnancies were 4.45 times and 12- to 15-fold greater than expected, respectively. LOY was associated with high-grade serous, low-grade serous, endometrioid, and clear cell histotypes (ORs per year increase = 1.054, 1.040, 1.065, and 1.098, respectively) but not mucinous tumors. Estimated coefficients of LOY components were close to expected estimates for high-grade serous but larger than expected for low-grade serous, endometrioid, and clear cell histotypes.

Conclusions

LOY is positively associated with nonmucinous EOC. Differences between estimated and expected model coefficients for LOY components suggest factors beyond ovulation underlie the associations between LOY components and EOC in general and for non-HGSOC.

Funding
Ovarian Cancer and Gonadotropin SignalingSURVEILLANCE EPIDEMIOLOGY AND END RESULTSEstablished Investigator Award Anti-Inflammatory Exposures in Cancer PreventionNIH HHS Grant P01CA17054Epidemiology of Ovarian Cancer:New HypothesesEstablished Investigator Award Anti-Inflammatory Exposures in Cancer PreventionDNA POLYMORPHISMS IN OVARIAN CANCER--CASE CONTROL STUDYCASE CONTROL STUDY OF OVARIAN CANCER HORMONAL ETIOLOGYRISK FACTOR ANALYSIS OF BRCA1 AND BRCA2 CARRIERSPathologyCancer Research Training and Education CoordinationOvarian Cancer and Gonadotropin SignalingCancer Risk Assessment, Early Detection, and Interception Research ProgramRelating Molecular Subgroups of Endometriosis-Associated Ovarian Cancers to Survival and RiskNIH HHS Grant R01-CA58598Medical Research Council (MRC) Grant MC_UU_00004/01Steroid Hormone Genes and Ovarian Cancer RiskSURVEILLANCE EPIDEMIOLOGY & END RESULTS PROGRAMThe Progesterone Receptor Gene and Ovarian Cancer RiskCollaborative Genetic Study of Ovarian Cancer RiskHormone Therapy and Risk of Ovarian CancerSURVEILLANCE EPIDEMIOLOGY AND END RESULTSSteroid Hormone Genes and Ovarian Cancer RiskProject 2: Next Generation TOP1 Inhibition for the Treatment of Ovarian CancerThe Ovarian Cancer Association Consortium FundingOvarian Cancer Research Fund FundingAustralian Ovarian Cancer Study FundingMedical Research and Materiel Command Grant DAMD17-01-1-0729National Health & Medical Research Council of Australia Grant 199600National Health & Medical Research Council of Australia Grant 400413National Health & Medical Research Council of Australia Grant 400281Cancer Councils of New South Wales FundingSouth Australia and Tasmania and Cancer Foundation of Western Australia FundingOvarian Cancer Australia FundingPeter MacCallum Foundation FundingUniversity of Erlangen-Nuremberg FundingRISK FACTOR ANALYSIS OF BRCA1 AND BRCA2 CARRIERSCASE CONTROL STUDY OF OVARIAN CANCER HORMONAL ETIOLOGYDNA POLYMORPHISMS IN OVARIAN CANCER--CASE CONTROL STUDYSteroid Hormone Genes and Ovarian Cancer RiskNational Institutes of Health (NIH) Grant R01-CA87538German Federal Ministry of Education and Research FundingProgramme of Clinical Biomedical Research FundingGerman Cancer Research Center FundingNational Institutes of Health Grant R01-CA58598In vitro and In Vivo screening of chemopreventive agentsCancer Genetic Network (CGN)Lon V Smith Foundation Grant LVS-39420National Institute for Health Research University College London Hospitals Biomedical Research Centre FundingNIH Grant P01CA17054NIH Grant P30CA14089NIH Grant R01CA61132NIH Grant N01PC67010The Progesterone Receptor Gene and Ovarian Cancer RiskCalifornia Cancer Research Program Grant 00-01389 V-20170California Cancer Research Program Grant 2II0200Established Investigator Award Anti-Inflammatory Exposures in Cancer Prevention

NIH HHS

K05-CA154337

NCI NIH HHS

R01 CA087538

NCI NIH HHS

K05 CA154337

NCI NIH HHS

R01 CA080742

NCI NIH HHS

R01 CA074850

NCI NIH HHS

R01 CA063678

NCI NIH HHS

P30 CA008748

NCI NIH HHS

P30 CA014089

NCI NIH HHS

R03 CA115195

NCI NIH HHS

P30 CA015083

NCI NIH HHS

R01 CA248288

NIH HHS

R01-CA112523

NCI NIH HHS

N01 PC067010

NCI NIH HHS

R03 CA113148

NCI NIH HHS

R01 CA058598

NCI NIH HHS

P01 CA017054

NCI NIH HHS

N01 CN025403

NCI NIH HHS

R01 CA112523

NCI NIH HHS

P50 CA136393

United States National Institutes of Health

R01-CA063678

United States National Institutes of Health

R01-CA074850

United States National Institutes of Health

R01-CA080742

National Institutes of Health

R01-CA112523

National Institutes of Health

N01-CN-55424

National Institutes of Health

N01-PC-67001

National Institutes of Health

R03CA113148

National Institutes of Health

R03CA115195

National Institutes of Health

N01CN025403

California Cancer Research Program

00-01389 V-20170

National Institutes of Health

K05-CA154337